AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6282302
Drug: Medium-fibre fine-bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-fibre fine-bran bread diet (22 g NDF/d)
Trial: 6282302
Drug: Wholemeal bread
RxNorm normalized name: Wholemeal bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wholemeal bread diet (22 g NDF/d)
Trial: 6282302
Drug: Coarse-bran bread
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coarse-bran bread diet (22 g NDF/d)
Trial: 6282302
Drug: Low-fibre white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fibre white bread diet (9 g NDF/d)
Trial: 31418933
Drug: Cornus mas
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cornus mas extract (CME) 300 mg, 3 capsules per day for 8 weeks
Trial: 31418933
Drug: Starch powder,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch powder, 3 capsules per day for 8 weeks
Trial: 28609534
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (3 mg/kg of elemental iron once daily for 12 weeks)
Trial: 28609534
Drug: Iron polysaccharide
RxNorm normalized name: iron polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron polysaccharide complex (3 mg/kg of elemental iron once daily for 12 weeks)
Trial: 26360834
Drug: Acamprosate calcium
RxNorm normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acamprosate calcium tablets (multiple dosing)
Trial: 26360834
Drug: Acamprosate calcium
RxNorm normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acamprosate calcium tablets (single dosing under fasting conditions)
Trial: 26360834
Drug: Acamprosate calcium
RxNorm normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acamprosate calcium tablets (single dosing under fed conditions)
Trial: 26360834
Drug: Acamprosate calcium
RxNorm normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acamprosate calcium tablets (bioequivalence evaluation)
Trial: 23642776
Drug: EVOO (50ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVOO (50ml daily)
Trial: 14988895
Drug: gamma radiation
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma radiation treatment (gamma‐RT)
Trial: 1406416
Drug: Cholestyramine 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 16 g/day
Trial: 1406416
Drug: Pravastatin (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (long-term treatment)
Trial: 1406416
Drug: Resin (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin (long-term treatment)
Trial: 1406416
Drug: Pravastatin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (12 weeks monotherapy)
Trial: 1406416
Drug: Resin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin (12 weeks monotherapy)
Trial: 3970333
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 0.25 mg/kg
Trial: 3970333
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 0.5 mg/kg
Trial: 3970333
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of diazepam (0.25 mg/kg and 0.5 mg/kg)
Trial: 3970333
Drug: Higher premedication
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher premedication dose (0.5 mg/kg)
Trial: 29474292
Drug: Pessary removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pessary removal daily
Trial: 29474292
Drug: Pessary removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pessary removal at least weekly
Trial: 29474292
Drug: Pessary removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pessary removal less often than once weekly
Trial: 27941661
Drug: Phosphorus supplementation
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphorus supplementation (500 mg)
Trial: 24398943
Drug: Alcohol (BrAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (BrAC up to 0.6 g/kg for 15 minutes followed by 100 minutes exposure)
Trial: 19069799
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment including physical factors (a constant magnetic field and negatively polarized phytoaeroions), soft‐tissue manual therapy, and dosed physical exercises.
Trial: 12517681
Drug: Drug withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug withdrawal program
Trial: 10799721
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (5 days per week)
Trial: 1563806
Drug: Barbiturates (high-dose)
RxNorm normalized name: 5-allyl-5-(2-methylpropyl)barbituric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbiturates (high-dose)
Trial: 1563806
Drug: Barbiturates (low-dose)
RxNorm normalized name: 5-allyl-5-(2-methylpropyl)barbituric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbiturates (low-dose)
Trial: 371650
Drug: i.v. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. injection of oxytocin 10 u
Trial: 371650
Drug: continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous infusion of dilute oxytocin
Trial: 21226679
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp)
Trial: 21226679
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement (5 mg melatonin, magnesium, and zinc)
Trial: 16620649
Drug: 1% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% silver sulfadiazine cream (Group B)
Trial: 12732773
Drug: Mesna solution
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna solution
Trial: 9862770
Drug: Cocaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (10 mg/70 kg)
Trial: 9862770
Drug: Cocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (20 mg/70 kg)
Trial: 9862770
Drug: Cocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (40 mg/70 kg)
Trial: 9862770
Drug: Nicotine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.75 mg/70 kg)
Trial: 11160635
Drug: Nicotine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (1.5 mg/70 kg)
Trial: 9862770
Drug: Nicotine (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (3.0 mg/70 kg)
Trial: 2178488
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lidocaine i.v.
Trial: 7203722
Drug: d,l‐oxyfedrine (Myofedrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l‐oxyfedrine (Myofedrin)
Trial: 7203722
Drug: l‐oxyfedrine (ildamen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐oxyfedrine (ildamen)
Trial: 31443627
Drug: Pilates-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates-based exercise treatment (n = 148)
Trial: 30141776
Drug: 3 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 monthly sessions with booster 3 months later (Group 1)
Trial: 27529709
Drug: Pneumatic broadband
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic broadband light (PBBL) plus adapalene gel 0.3%
Trial: 27529709
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel 0.3% monotherapy
Trial: 24619106
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (600 mg)
Trial: 24619106
Drug: Dairy products
RxNorm normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy products (600 mg)
Trial: 20573799
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake (quintiles: 22, 135, 285, 402, and 656 mg/d)
Trial: 18638410
Drug: Osteopathy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathy treatment (n = 15 infants)
Trial: 7730703
Drug: 18 monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 monthly doses of WHO/MDT
Trial: 7730703
Drug: 30 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30 monthly doses of WHO/MDT
Trial: 2210598
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine orally one hour prior to anesthetic induction
Trial: 2210598
Drug: Nifedipine infusion
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine infusion of 0.30 micron/kg/min prior to extracorporeal circulation
Trial: 2210598
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nifedipine infusion)
Trial: 7378259
Drug: Debrisoquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debrisoquine (30 mg oral dose)
Trial: 7378259
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg p.o.) given 2 h before debrisoquine
Trial: 7378259
Drug: Chronic debrisoquine
RxNorm normalized name: Debrisoquine
DrugBank: Debrisoquine (DB04840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic debrisoquine therapy
Trial: 31111502
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (PRT) with a median dose of 73.8 Gy (RBE; range 68.4-79.2 Gy); 17 patients received adjuvant PRT, 3 received definitive PRT; PRT-only (n=6) or combination PRT/intensity-modulated radiotherapy (IMRT) (n=14)
Trial: 28641030
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4 combined with 3 mg DRSP
Trial: 28641030
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg E4 combined with 3 mg DRSP
Trial: 28641030
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4 combined with 150 μg LNG
Trial: 28641030
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg E4 combined with 150 μg LNG
Trial: 23748252
Drug: Pregabalin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75 mg twice per day) and celecoxib (100 mg twice per day) for 14 days before THA and for three weeks after discharge.
Trial: 21426884
Drug: 1,600 mg
RxNorm normalized name: omega-3/dha/epa/fish oil 1,600 mg-500 mg-800 mg/5 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,600 mg of MESNA plus 0.9% saline
Trial: 20052918
Drug: Cycloferon addition
RxNorm normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloferon addition to main therapy
Trial: 20052918
Drug: Main therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Main therapy without cycloferon
Trial: 18411913
Drug: Hormonal supplement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal supplement therapy per oss (HST)
Trial: 18411913
Drug: Transdermal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo (Control)
Trial: 15132876
Drug: Phenoxybenzamine-hydrochloride: 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine-hydrochloride: 10 mg two times a day for one month
Trial: 15132876
Drug: Flavoxate HCI-neptumus:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavoxate HCI-neptumus: 200 mg three times a day for one month
Trial: 31322116
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g intravenous bolus followed by an 8‐hour 1‐g infusion)
Trial: 20197354
Drug: Telemedicine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine treatment for 4 months
Trial: 20197354
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for 4 months
Trial: 20197354
Drug: Telemedicine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine treatment after conventional therapy
Trial: 20197354
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment after telemedicine therapy
Trial: 19347813
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and insulin concentrations in 0', 30', 60' of OGTT in obese women
Trial: 12050268
Drug: rhIGF‐I (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (30 microg/kg sc twice daily) and oral contraceptive (Ovcon 35, 35 microg ethinyl estradiol and 0.4 mg norethindrone)
Trial: 12050268
Drug: rhIGF‐I alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I alone (30 microg/kg sc twice daily)
Trial: 12050268
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive alone
Trial: 12050268
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active therapy
Trial: 1375685
Drug: Anistreplase (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anistreplase (doses ranging from 3.75 to 35 IU, 60% received 30 IU)
Trial: 1375685
Drug: Delay from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay from onset of symptoms to treatment
Trial: 25985403
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir (PrEP)
Trial: 3455212
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (ST)
Trial: 3455212
Drug: Non-steroid treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid treatment (NT)
Trial: 16814890
Drug: Fermented millet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented millet drink (KSW) 300 ml daily for 5 days
Trial: 16814890
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for diarrhoea at local clinic
Trial: 7944428
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of ADM or MMC
Trial: 7944428
Drug: No regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No regional chemotherapy
Trial: 7944428
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 5-FU
Trial: 7944428
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local chemotherapy
Trial: 3232498
Drug: Nalbuphine 20
RxNorm normalized name: nalbuphine 20 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 20 mg I.M.
Trial: 3232498
Drug: Pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 30 mg I.M.
Trial: 25276627
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (1g)
Trial: 20822500
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg of polaprezinc in addition to standard therapies
Trial: 20822500
Drug: Standard therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapies only
Trial: 7520857
Drug: Appetite stimulants
RxNorm normalized name: APPETITE STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appetite stimulants (specifics not provided)
Trial: 7520857
Drug: Enteral and
RxNorm normalized name: Enteral and supplement feeds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral and parenteral alimentation (under evaluation)
Trial: 28050704
Drug: Swallowing action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing action immediately before intravenous fentanyl (S group)
Trial: 19674724
Drug: Maximum limit
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum limit statements (e.g., maximum distances, maximum durations, maximum prices, maximum delivery times)
Trial: 17344008
Drug: Brachytherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachytherapy with Ir-192 (mean dose 30 Gy) and external radiotherapy (mean dose 50 Gy)
Trial: 11303344
Drug: Anti-reflux treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-reflux treatment in reflux positive HRAD patients
Trial: 11303344
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for reflux in reflux negative HRAD patients
Trial: 7988260
Drug: CAP (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP (cyclophosphamide, doxorubicin, cisplatin) chemotherapy plus radiation therapy as preoperative or neoadjuvant therapy
Trial: 2691239
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support diet (50 kcal/kg bodyweight/d and 1.5 g protein/kg bodyweight/d)
Trial: 21929600
Drug: Continuous sublingual
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sublingual immunotherapy (SLIT)
Trial: 21929600
Drug: Coseasonal sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coseasonal sublingual immunotherapy (SLIT)
Trial: 15706659
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg OW
Trial: 15706659
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg OW
Trial: 9129791
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension (1 ml of phosphate‐buffered saline)
Trial: 26939828
Drug: Bioptron light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioptron light therapy + cryotherapy
Trial: 31209191
Drug: Oral Na/K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Na/K citrate plus saline infusion (treatment group)
Trial: 31209191
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water plus saline infusion (placebo group)
Trial: 31209191
Drug: CIN-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIN-positive patients in treatment group
Trial: 27889832
Drug: Selumetinib 25
RxNorm normalized name: selumetinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib 25 mg co-administered with itraconazole 200 mg twice daily (study A)
Trial: 27889832
Drug: Selumetinib 25
RxNorm normalized name: selumetinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib 25 mg co-administered with fluconazole 400 mg on day 1 then 200 mg/day (study A)
Trial: 27889832
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg co-administered with rifampicin 600 mg/day (study B)
Trial: 27889832
Drug: Selumetinib 25
RxNorm normalized name: selumetinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib 25 mg alone (study A)
Trial: 27889832
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg alone (study B)
Trial: 27889832
Drug: Selumetinib co-administered
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib co-administered with itraconazole (study A)
Trial: 27889832
Drug: Selumetinib co-administered
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib co-administered with rifampicin (study B)
Trial: 27889832
Drug: Selumetinib co-administered
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib co-administered with fluconazole (study A)
Trial: 23656463
Drug: Soy supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplement diet (Soy Group, SG; n = 72)